Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPSC-derived Th1 cells
- Development stage
- Preclinical
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
iPSC-derived Th1 cells are T helper type 1 (Th1) lymphocytes generated from induced pluripotent stem cells (iPSCs). iPSCs are somatic cells reprogrammed to a pluripotent state, enabling them to differentiate into various cell types, including immune lineages such as T lymphocytes. The process involves directing iPSCs through hematopoietic and then T-cell differentiation pathways, followed by polarization toward the Th1 phenotype. These engineered immune effector cells can be used for immunotherapy applications, particularly in cancer and infectious diseases, due to their ability to produce interferon-gamma and mediate cellular immunity. The approach aims to provide an "off-the-shelf" source of functional Th1 T-cells for adoptive cell therapy[7][2]. Research is ongoing regarding their safety, efficacy, and scalability.
- Other names
- induced pluripotent stem cell-derived Th1 cellsiPSC-Th1 cellsiPSC-Th-1 cellsiPSC-Th 1 cells
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on iPSC-derived Th1 cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPSC-derived Th1 cells.